Since Zeb-1 has been previously reported by our group to be an important therapeutic target that correlates with patient overall survival and BTZ resistance in MCL via cancer stem cell regulation [32], we next performed database analysis based on mRNA expression of CD36 and co-expression of CD36 and ZEB1 in human MCL microarrays available on Gene Expression Omnibus (GEO; accession number GSE10793) [33] to examine their association to clinical outcome. This evidence concerns the gene CD36 and mantle cell lymphoma.